Women who take less insulin than required to manage type 1 diabetes could be cutting their lifespan by more than a decade, say researchers at Boston’s Joslin Diabetes Center. Published in the journal Diabetes Care, the 11-year follow-up study showed that out of 234 type 1 diabetic women, those who limited their insulin intake increased their risk of death and had higher rates of kidney and foot problems than women who did not limit their... read more
Submitted by Gabby
Needles are banned from both household trash and trash cans in public places like parks.
Submitted by Amy Tenderich
Injecting a cocktail of proteins directly into the bodies of diabetic mice, researchers have converted normal pancreas cells into insulin-producing cells -- a genetic transformation that could pave the way for treating intractable diseases and injuries using a patient's own supply of healthy tissue.
The Harvard University scientists activated a trio of dormant genes that commanded the cells to transform themselves, much as a person might upload a new operating system onto a computer to... read more
Submitted by BarryE
Transplantation of insulin-producing cell islets, so-called islets of langerhans is an appealing strategy for treatment of type 1 diabetes. But it turns out that these are short-lived, and the procedure needs to be repeated.
Now researchers at Linköping University and Uppsala University in Sweden can show that accumulation of protein aggregatess, amyloid, in the transplanted cells may be causing their death.
Until now it was not known why this insulin production ceases. The discovery now... read more
Submitted by BarryE
<p>Dr. Roger Unger, chair of diabetes research at UT Southwestern Medical School, is quick to warn that practical applications, if any, are years away. </p>
<p>If the experiment is repeated in other labs, and then if leptin can be adapted to treat humans, it might offer the first alternate to the multiple insulin injections used by millions of people who have type 1 diabetes, Dr. Unger said. </p>
<p>How surprising was the result... read more
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced successful results from the clinical trial of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a good safety profile and well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.
The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that... read more
Submitted by BarryE
CHICAGO, August 7, 2008—The American Association of Diabetes Educators (AADE) today announced results from a survey conducted by Harris Interactive highlighting communication between people with diabetes that require insulin injections and their healthcare providers. According to the survey results, 33 percent of respondents have experienced some level of dread relating to insulin injections (eight percent strongly agreed/25 percent somewhat agreed), 14 percent of individuals surveyed felt that the insulin injections had a negative impact on... read more
Submitted by BarryE
A researcher at the University of Central Florida says he has created a strain of lettuce that creates insulin.
Mike Beckman for the past 34 years has had to manage his Type 1 diabetes.
"It is with you every day," said Beckman.
He's had bleeding in his eyes, a heart attack, nerve damage and now, both of his kidneys are failing. It's also taking a toll on his family.
Submitted by BarryE
Researchers have used a drug to achieve normal levels of blood sugar in animals genetically engineered to have abnormally high insulin levels. If this approach succeeds in humans, it could become an innovative medicine for children with congenital hyperinsulinism, a rare but potentially devastating genetic disease in which insulin levels become dangerously high.
"There is currently no effective medical treatment for children with the most common type of congenital hyperinsulinism," said study leader Diva D.... read more
Submitted by BarryE
New study results in the July issue of Diabetes Care, the American Diabetes Association's medical journal, found two different mealtime insulin dosing algorithms using a "basal-bolus" treatment strategy were highly effective for patients with type 2 diabetes. The study, which examined more than 270 intent to treat patients, resulted in significant post-prandial glucose and A1C reductions.
Both algorithms examined basal-bolus treatment with long-acting (basal) insulin Lantus and rapid-acting (bolus) insulin Apidra.
Submitted by BarryE